There’s really no such thing as a “no brainer” stock pick. I’d say that some opportunities are more compelling than others.

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to ...

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure We continue to believe AbbVie needs to expand its late-stage pipeline.

AbbVie’s focus on building a strong portfolio, particularly in immunology and neurology, further supports the Buy rating. The company’s plans to enhance its offering with promising trial ...

With a diversified portfolio in immunology, oncology, aesthetics, neuroscience, and eye care, AbbVie Inc has shown a resilient financial performance.

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The ...

AbbVie's impressive Q2 2024 financial results show surging sales in immunology and neuroscience. Read why I continue to cover ABBV stock with a 'Buy' rating.

Less than a year ago, AbbVie's star immunology drug Rinvoq picked up its seventh FDA approval< | AbbVie's Rinvoq has racked up seven FDA approvals in recent years, and another expansion into giant ...